Clicky

Nektar Therapeutics(ITH)

Description: Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.


Keywords: Cancer Biopharmaceutical Inflammation Autoimmunity Autoimmune Disorders Ucb Tumor Necrosis Factor Chronic Inflammatory Conditions Nektar Therapeutics Regulatory T Cell

Home Page: www.nektar.com

455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
Phone: 415 482 5300


Officers

Name Title
Mr. Howard W. Robin CEO, President & Director
Ms. Sandra A. Gardiner Chief Financial Officer
Mr. Mark A. Wilson J.D. Senior VP, Chief Legal Officer & Secretary
Dr. Jonathan Zalevsky Ph.D. Chief Research & Development Officer
Ms. Vivian Wu Director of Investor Relations & Corporate Affairs
Mr. Robert Bacci Senior Vice President of Human Resources & Facilities Operations
Ms. Jennifer Ruddock Chief Business Officer
Dr. Mary Tagliaferri L.Ac., M.D. Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.7826
Price-to-Sales TTM: 1.9217
IPO Date:
Fiscal Year End: December
Full Time Employees: 137
Back to stocks